Article
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.
Signal transduction and targeted therapy - 28 Nov 2025
Choucair Khalil, Imtiaz Hafsa, Uddin Md Hafiz, Nagasaka Misako, Al-Hallak Mohammad Najeeb, Philip Philip A, El-Rayes Bassel, Pasche Boris C, Azmi Asfar S
Abstract excerpt
Activating KRAS mutations are highly relevant to various cancers, and KRAS is the most frequently altered oncogenic protein in solid tumors. While historically considered undruggable, two KRASG12C inactive state-selective inhibitors are currently approved for treating patients with non-small cell lung cancer. However, these agents only demonstrate a 30-40% response rate and a median progression-free survival of...
Topics
- Humans
- Proto-Oncogene Proteins p21(ras)
- Mutation
- Neoplasms
- Drug Resistance, Neoplasm
- Tumor Microenvironment
- Molecular Targeted Therapy
- Signal Transduction